Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 226   

Articles published

SNY 52.79 -0.50 (-0.94%)
price chart
FDA Approves Sanofi's Breakthrough Gaucher Disease Drug
The US Food and Drug Administration (FDA) announced Tuesday, that it has approved Sanofi SA (ADR)'s (SNY) new drug Cerdelga, which is a first-line oral treatment for adults with type 1 Gaucher disease, a rare genetic disorder.
Related articles »  
Sanofi Raises Guidance After Second-Quarter Profit Jump
Sanofi SA (ADR) (SNY) beat the Street's earnings expectations for the second quarter of its fiscal year '14 (2QFY14, ended June 30); the company then raised its full-year guidance.
Related articles »  
Sanofi To Sell Mature Drugs Portfolio
Sanofi SA (ADR) (SNY) wishes to divest its portfolio of old drugs whose patents have expired or are due to expire. As per a document circulated by the CGT labor union, the Paris-based pharmaceutical company plans to divest 200 mature products from its ...
Related articles »  
Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza ...
Boston, MA 08/11/2014 (wallstreetpr) - French drug company Sanofi SA (ADR) (NYSE:SNY) and MannKind Corporation (NASDAQ:MNKD) have entered a global collaboration that involves developing and marketing of the inhaled insulin therapy, Afrezza, ...
Sanofi SA (ADR) (NYSE:SNY) Walks Out From KaloBios Pharmaceuticals Inc ...
Boston, MA 07/29/2014 (wallstreetpr) - During the 2013′s era of biotech boom, KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) had debuted on the exchange with high promises to deliver, which had instantly caught attention of giants like Sanofi SA (ADR) ...
Related articles »  
FDA Approves Genzyme's Lumizyme For All Ages
Genzyme, a subsidiary of Sanofi SA (ADR) (SNY), announced last Friday, the US Food & Drug Administration's (FDA) approval of Lumizyme (Alglucosidase Alfa) for treating all patients suffering from infantile-onset Pompe disease, including those under the ...
Related articles »  
Pfizer Inc. (NYSE:PFE) May See Lawsuit as Sanofi SA (NYSE:SNY ...
Sanofi Pasteur, the vaccines division of Sanofi SA (ADR) (NYSE:SNY) [Trend Analysis] reported that The New England Journal of Medicine published optimistic results from a large-scale, multi-center efficacy trial, which found that Fluzone High-Dose ...
Related articles »  
Best Pharma Stocks Not In The U.S. [GlaxoSmithKline plc (ADR), AbbVie Inc ...
healthcare1 Marshall Hargrave: With tax inversions being one of the hottest topics in the merger and acquisition market these days, pharma stocks are in full focus.
Three Stocks To Watch: Microsoft Corporation (NASDAQ:MSFT), Sanofi SA ...
Sanofi SA (ADR) (NYSE:SNY)'s President of North American Pharma unit, Anne Whitaker is possibly leaving the company to pursue �another� opportunity.
Stocks on Trader's Radar � Sanofi SA (ADR) (NYSE:SNY), Sequenom, Inc ...
Las Vegas, NV - August 16, 2014 - (TechSonian) �Sanofi SA (ADR)(NYSE:SNY) reported that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that Fluzone� High-Dose (Influenza ...